Analytical and clinical performance of the Ortho-Clinical Diagnostics VITROS® amino-terminal pro-B type natriuretic peptide assay

Januzzi, James L.; Lewandrowski, Kent; Bashirians, George; Jackson, Shari; Freyler, Deb; Smith, Katrina; Murakami, MaryAnn M.; Apple, Fred S.

doi:10.1016/j.cca.2007.08.018

Cited by 8 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NT‐proBNP levels were determined by the VITROS NT‐proBNP Assay (Ortho‐Clinical Diagnostics, Raritan, NJ). The full analysis of the analytical and clinical performance of the VITROS NT‐proBNP assay has been previously reported 12. The assay has been shown to have acceptable levels of imprecision, a limit of detection of 4.29 ng/L, and a limit of quantification estimated to be 5.0 ng/L.…”

Section: Methodsmentioning

confidence: 99%

Interaction of Body Mass Index on the Association Between N‐Terminal‐Pro‐b‐Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)

Bhatt

Cooper

Ambrosy

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundHigher body mass index (BMI) is associated with lower circulating levels of N‐terminal‐pro‐b‐type natriuretic peptide (NT‐proBNP). The Interaction between BMI and NT‐proBNP with respect to clinical outcomes is not well characterized in patients with acute heart failure.Methods and ResultsA total of 686 patients from the biomarker substudy of the ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated HF ) clinical trial with documented NT‐proBNP levels at baseline were included in the present analysis. Patients were classified by the World Health Organization obesity classification (nonobese: BMI <30 kg/m2, Class I obesity: BMI 30–34.9 kg/m2, Class II obesity BMI 35–39.9 kg/m2, and Class III obesity BMI ≥40 kg/m2). We assessed baseline characteristics and 30‐ and 180‐day outcomes by BMI class and explored the interaction between BMI and NT‐proBNP for these outcomes. Study participants had a median age of 67 years (55, 78) and 71% were female. NT‐proBNP levels were inversely correlated with BMI (P<0.001). Higher NT‐proBNP levels were associated with higher 180‐day mortality (adjusted hazard ratio for each doubling of NT‐proBNP, 1.40; 95% confidence interval, 1.16, 1.71; P<0.001), but not 30‐day outcomes. The effect of NT‐proBNP on 180‐day death was not modified by BMI class (interaction P=0.24).ConclusionsThe prognostic value of NT‐proBNP was not modified by BMI in this acute heart failure population. NT‐proBNP remains a useful prognostic indicator of long‐term mortality in acute heart failure even in the obese patient.Clinical Trial RegistrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00475852.

show abstract

Section: Methodsmentioning

confidence: 99%

Interaction of Body Mass Index on the Association Between N‐Terminal‐Pro‐b‐Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)

Bhatt

Cooper

Ambrosy

et al. 2018

JAHA

View full text Add to dashboard Cite

show abstract

VITROS ® ECiQ Immunodiagnostic System, VITROS ® 3600 Immunodiagnostic System, and VITROS ® 5600 Integrated System

Backus¹,

Wild²

2013

The Immunoassay Handbook

View full text Add to dashboard Cite

Prognostic Implications of Changes in Amino-Terminal Pro–B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF

Grodin

Liebo

Butler

et al. 2019

Journal of Cardiac Failure

View full text Add to dashboard Cite

Background: Amino-terminal proÀB-type natriuretic peptide (NTproBNP) is closely associated with prognosis in acute decompensated heart failure (ADHF). As a result, there has been great interest measuring it during the course of treatment. The prognostic implications in both short-term and follow-up changes in NTproBNP need further clarification. Methods: Baseline, 48À72 hour, and 30-day NTproBNP levels were measured in 795 subjects in the ASCEND-HF trial. Multivariable logistic and Cox-proportional hazards models were used to test the association between static, relative, and absolute changes in NTproBNP with outcomes during and after ADHF. Results: The median NTproBNP at baseline was 5773 (2981À11,579) pg/mL; at 48À72 hours was 3036 (1191À6479) pg/mL; and at 30 days was 2914 (1364À6667) pg/mL. Absolute changes in NTproBNP by 48À72 hours were not associated with 30-day heart failure rehospitalization or mortality (P = .065), relative changes in NTproBNP were nominally associated (P = .046). In contrast, both absolute and relative changes in NTproBNP from baseline to 48À72 hours and to 30 days were closely associated with 180-day mortality (P < .02 for all) with increased discrimination compared to the multivariable models with baseline NTproBNP (P <.05 for models with relative and absolute change at both time points). Conclusions: Although the degree of absolute change in NTproBNP was dependent on baseline levels, both short-term absolute and relative changes in NTproBNP were independently and incrementally associated with long-term clinical outcomes. Changes in NTproBNP levels at 30-days were particularly well associated with long-term clinical outcomes.

show abstract

Analytical and clinical performance of the Ortho-Clinical Diagnostics VITROS® amino-terminal pro-B type natriuretic peptide assay

Cited by 8 publications

References 29 publications

Interaction of Body Mass Index on the Association Between N‐Terminal‐Pro‐b‐Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)

Interaction of Body Mass Index on the Association Between N‐Terminal‐Pro‐b‐Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)

VITROS ® ECiQ Immunodiagnostic System, VITROS ® 3600 Immunodiagnostic System, and VITROS ® 5600 Integrated System

Prognostic Implications of Changes in Amino-Terminal Pro–B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF

Contact Info

Product

Resources

About